How Dupixent Works
Dupixent (dupilumab) is a fully human monoclonal antibody that blocks the IL-4 receptor alpha subunit (IL-4Rα), thereby inhibiting signaling from both IL-4 and IL-13, two key cytokines that drive type 2 inflammatory responses. 1
Mechanism of Action
Dupilumab specifically binds to IL-4Rα, which is a shared component of two receptor complexes 1:
- Type I receptor (IL-4Rα/γc): Responds to IL-4 only
- Type II receptor (IL-4Rα/IL-13Rα1): Responds to both IL-4 and IL-13
By blocking IL-4Rα, dupilumab simultaneously prevents both IL-4 and IL-13 from activating their downstream inflammatory pathways 2.
Biological Effects
IL-4 and IL-13 are potent mediators of type 2 immunity with overlapping functions 2. When dupilumab blocks these pathways, it produces several anti-inflammatory effects:
Direct Cellular Effects
- Reduces IgE production: IL-4 and IL-13 drive B cells to switch to IgE production; blocking them decreases total and allergen-specific IgE 2, 1
- Decreases eosinophil activation: Both cytokines activate eosinophils, key inflammatory cells in type 2 diseases 2
- Reduces mucus secretion: IL-4 and IL-13 stimulate goblet cells to overproduce mucus 1
- Prevents airway remodeling: These cytokines contribute to structural changes in affected tissues 2
Immune System Modulation
IL-4 is a major differentiation factor that drives naive T cells toward the TH2 subtype 2. By blocking IL-4 signaling, dupilumab:
- Prevents TH2 cell differentiation
- Reduces production of other type 2 cytokines (IL-5, IL-9, IL-13)
- Decreases chemokines like TARC and eotaxin that recruit inflammatory cells 2
Barrier Function
IL-4 and IL-13 downregulate filaggrin expression in keratinocytes, contributing to epidermal barrier disruption 3. They also:
- Downregulate cutaneous defensins (antimicrobial peptides)
- Increase bacterial adhesion molecules, facilitating Staphylococcus aureus colonization 3
Dupilumab reverses these effects by blocking the cytokine signals.
Measurable Biomarker Changes
When dupilumab blocks IL-4 and IL-13 signaling, several inflammatory markers decrease 1:
- Fractional exhaled nitric oxide (FeNO): Decreases by 24-35% within 2 weeks
- Total IgE: Median reduction of 52% at 24 weeks and 70% at 52 weeks
- Eosinophil markers: Eotaxin-3, TARC, and periostin all decrease
- Allergen-specific IgE: Reduced relative to baseline
These biomarker reductions occur rapidly (within 2 weeks for most markers except IgE, which declines more slowly) and are sustained throughout treatment 1.
Clinical Translation
The mechanism explains dupilumab's efficacy across multiple type 2 inflammatory diseases 1:
- Atopic dermatitis: Restores skin barrier function, reduces inflammation and itch
- Asthma: Reduces airway inflammation, prevents exacerbations, improves lung function
- Chronic rhinosinusitis with nasal polyps: Shrinks polyps, reduces sinus inflammation
- Eosinophilic esophagitis: Decreases esophageal eosinophilia and inflammation
- Prurigo nodularis: Reduces inflammatory nodules and itch
- COPD: Reduces type 2 inflammation-driven exacerbations
The shared pathophysiology across these conditions—driven by IL-4 and IL-13—explains why a single drug targeting IL-4Rα can effectively treat multiple seemingly distinct diseases 4.
Important Caveat
While the mechanism involves blocking IL-4 and IL-13 signaling through IL-4Rα, the precise mechanism by which this translates to clinical benefit has not been definitively established 1. The drug's effects on multiple cell types (mast cells, eosinophils, macrophages, lymphocytes, epithelial cells, goblet cells) and inflammatory mediators (histamine, eicosanoids, leukotrienes, cytokines, chemokines) likely all contribute to its therapeutic effects 1.